Todd Hembrough - Concepedia

Author

Todd Hembrough

Also Known As

T Hembrough, T. A. Hembrough, T. Hembrough, T.A. Hembrough, Todd A Hembrough, Todd A. HEMBROUGH, Todd A. Hembrough, Todd Hembrough

248

Publications

4.5K

Citations

H-Index

Concepts

All Affiliations

OncoPlex Diagnostics (United States)University of Chicago Memorial Sloan Kettering Cancer Center Cornell University CASI Pharmaceuticals (United States)

About

Todd Hembrough is an author at OncoPlex Diagnostics (United States) specializing in medicine, cancer research, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	17	2.3K
2	Cell Biology	7	7	1.1K
3	Engineering	3	3	126
4	Health Sciences	2	2	207
5	Biomedical Engineering	1	1	64

Todd Hembrough

Publications

4.4K

Citations

H-Index

Page 1

	Year	Citations
Ado-Trastuzumab Emtansine for Patients With <i>HER2</i>-Mutant Lung Cancers: Results From a Phase II Basket Trial Bob T. Li, Ronglai Shen, Darren J. Buonocore, Journal of Clinical Oncology Tumor BiologyPartial Response RateMedicineImmunologyMass Spectrometry	2018	541
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS Zhan Yao, Rona Yaeger, Vanessa Rodrik-Outmezguine, Nature OncologyActivated RasClass 3Oncogenic AgentMedicine	2017	540
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade Qu Zhang, Jia Luo, Song Wu, Cancer Discovery	2020	323
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition Gabrielle S. Wong, Jin Zhou, Jie Bin Liu, Nature Medicine Tumor BiologyOncologyEsophageal CancerGastrointestinal OncologyMedicine	2018	268
Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Todd Hembrough, Glenn M. Swartz, Adonia E. Papathanassiu, PubMed ImmunologyTumor BiologyThrombosisAngiogenesisCoagulation Inhibitors	2003	197
Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study Maud Toulmonde, Marina Pulido, Isabelle Ray‐Coquard, The Lancet Oncology OncologyCombination ChemotherapyMetronomic TherapyProgressive Desmoid TumoursPharmacotherapy	2019	193
Therapeutic Promise of Proteinase-Activated Receptor-2 Antagonism in Joint Inflammation Elizabeth B. Kelso, John C. Lockhart, Todd Hembrough, Journal of Pharmacology and Experimental Therapeutics	2006	192
An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer Luciano G. Martelotto, Timour Baslan, Alberto Vides, Nature Medicine Systems BiologyMedicineTreatment ResistanceResistance Mutation (Virology)Brafv600e-mutant Cancer	2017	173
<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i> -Amplified Esophagogastric Cancer Francisco Sánchez-Vega, Jaclyn F. Hechtman, Pau Castel, Cancer Discovery	2018	140
ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action Graham C. Fletcher, Richard D. Brokx, Trisha A. Denny, Molecular Cancer Therapeutics	2010	128

Page 1